Skip to main content
. 2021 Jul 8;6(13):e143385. doi: 10.1172/jci.insight.143385

Figure 4. ACTH prolongs heart allograft survival in the absence of PI3Kγ.

Figure 4

Comparison of heart allograft survival among PI3KγKO recipients of BALB/c hearts that received either ACTH (n = 5; MST, 30 days) or no treatment (Control; n = 11; MST, 10 days), and PI3Kγfl/fl-CD4-Cre recipients of BALB/c hearts that received either ACTH (n = 4; MST, 29 days) or no treatment (control; n = 9; MST, 8.6 days). *P < 0.05, **P < 0.01 by log-rank test.